Amgen
Amgen’s deCODE Reveals New Clonal Hematopoiesis Risk Factors and Genes
Amgen’s subsidiary, deCODE Genetics, has uncovered new risk factors and genes associated with clonal hematopoiesis, a precursor condition to blood ...
Amgen’s Wezlana Emerges as Competitor to J&J’s Stelara, Shaping Medicare Negotiations
Johnson & Johnson may find a silver lining in the recent FDA approval of Amgen’s biosimilar for Stelara. This approval ...
Amgen Secures FDA Approval for Stelara Biosimilar, Awaits 2025 Launch Post-Settlement
The FDA has granted approval to Amgen for its biosimilar rendition of Johnson & Johnson’s renowned autoimmune medication, Stelara. However, ...
Amgen to cut 350 jobs after acquiring Horizon for $28 billion
Recently, in the aftermath of Amgen’s substantial $27.8 billion acquisition of Horizon, unveiled in December and finalized this month, these ...
Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)
ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...
Phase II DeLLphi-301 Study Reveals Impressive Antitumor Activity of Amgen’s First-in-Class Bispecific Antibody Tarlatamab (ESMO 2023)
ESMO 2023: LBA92 Most SCLC patients are diagnosed with cancer that has already spread beyond the lungs, and their average ...
Astria buys rights to Ichnosâ eczema drug for $15M, joining crowded field of Amgen and Sanofi
Ichnos Sciences has secured a buyer for its OX40 eczema program, with Astria Therapeutics entering the scene by paying an ...
Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution
Amgen has successfully concluded its monumental $27.8 billion acquisition of Horizon Therapeutics, triumphing over a legal challenge posed by the ...
Amgenâs Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...
FDA Identifies ‘Systemic Bias’ in Amgen’s Late-Stage Lumakras Trial Ahead of Adcomm
As an FDA advisory committee prepares to deliberate on the data supporting Amgen’s groundbreaking drug Lumakras, a pre-meeting briefing document ...
How Tezspire helps a punk rocker with severe asthma live his life to the fullest
Amgen and AstraZeneca are making a triumphant return to television advertising to highlight how Tezspire is transforming the lives of ...
Amgen Unveils Exciting First-Line KRAS G12C NSCLC Data: Lumakras (Sotorasib) with Chemotherapy Shines at WCLC
Amgen has unveiled exciting findings from a segment of the CodeBreaK 101 clinical trial, a Phase 1b study investigating the ...
Amgenâs Otezla holds its ground against BMSâ Sotyktu in oral plaque psoriasis market, leaving room for J&Jâs potential game-changer
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
Amgen seals the deal with Horizon for $28 billion, expanding its portfolio of rare disease drugs
After several months of legal battles, Amgen has finally received the green light for its $27.8 billion acquisition of Horizon ...
Navigating the Maze of “Bad Cholesterol”: A Wake-Up Call for Heart Survivors
In the delicate realm of heart health, where knowledge often stands as a shield against future battles, a surprising chasm ...
FTC’s Legal Pas de Deux: A Pause in the Amgen-Horizon Acquisition
In the world of corporate clashes and strategic maneuvers, a legal ballet is unfolding, with the Federal Trade Commission (FTC) ...
Amgen’s Groundbreaking Discovery: Unleashing the Potential of Olpasiran Beyond Expectations
In a revelation that promises to reshape the landscape of cardiovascular health, biotechnology giant Amgen has unveiled extraordinary findings from ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
Amgen challenges FTCâs bid to block $28B Horizon deal
Amid the ongoing legal battle with the Federal Trade Commission (FTC) over its $28 billion acquisition of Horizon Therapeutics, Amgen ...
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
Amgen Takes a Playful Approach with Otezla Advertisement Amid Growing Competition in the Psoriasis Market
Amgen, a major biotech company, has taken an innovative approach to connect with psoriasis patients by using humor in their ...
Novartis Invests $60 Million Upfront in Ionis’ Innovative Cardiovascular Medication
Source – Ionis Pharmaceuticals Novartis has enlisted Ionis to develop another drug for cardiovascular disease, investing $60 million in a ...
